Vitura Health has opened FY2027 with a sharp improvement in EBITDA and lower operating costs, while revenue growth continued across its digital health businesses. The figures are unaudited, and the company still needs to prove that the improvement can survive the wind-down of Bupa-related telehealth volumes.
- Revenue up 4.8% year on year to start FY2027
- Unaudited EBITDA rises 197.5% against the prior corresponding period
- Operating expenditure falls 9.5%, or $685,000
- Medical cannabis dispensing volumes increase 19% from Q4 FY2026
- Three Horizon Plan targets profitability over the next 12 to 18 months
EBITDA improvement puts profitability back in focus
Vitura Health Limited (ASX:VIT) has started FY2027 with its clearest financial improvement in some time: unaudited EBITDA rose by $1.01 million, or 197.5%, against the prior corresponding period, while operating expenditure fell by $685,000. Revenue increased 4.8%, or $1.7 million.
The company did not disclose absolute revenue, EBITDA, cash flow or net profit figures in the operational update, so the percentage gains do not establish that Vitura has returned to profitability. They do, however, show the direction of travel management is pursuing after a half-year loss and margin pressure in the previous financial year. That earlier result included an $986,341 consolidated loss after tax and declining gross margins in a competitive medicinal cannabis market, making cost control a material part of the recovery story.
Three Horizon Plan targets the operating base
The board has endorsed Vitura’s Three Horizon Plan, with the first 12 to 18 months devoted to improving patient access, fulfilment, internal systems and processes, clinical governance, contracting and margin stability. Expense discipline is also listed as a central workstream.
Vitura says work on the first horizon is already under way and plans to provide more detail at its annual general meeting on 27 November 2026. The plan gives the improved first-quarter numbers a framework, but its success will depend on whether lower costs can be maintained without weakening patient access or the businesses’ ability to grow.
Medical cannabis volumes and pharmacy sales strengthen
Candor and Canview both contributed to the quarter. Candor recorded higher overall patient consultations, particularly check-up consultations, while medical cannabis dispensing volumes increased 19% from the fourth quarter of FY2026. Vitura also said margins on those sales continued to improve.
Canview benefited from a promotional program aimed at pharmacies, which the company said delivered strong sales growth. The platform’s performance matters because it links Vitura’s prescribing, ordering and pharmacy distribution operations, although the update does not quantify the program’s contribution or disclose whether the improvement will persist beyond the quarter.
Doctors on Demand faces a post-Bupa test
Doctors on Demand revenue exceeded expectations in the quarter, supported by higher consultation numbers and continued Bupa consultations. Underlying consultation volumes, excluding Bupa International patients, also remained above expectations. The business had already reported sustained EBITDA profitability and more than one million consultations since FY2024 in its previous financial-year update, but its next test is different: converting demand into an efficient operating base as contracted volumes change.
The Bupa International Student transition is complete, while the International Visitor transition began on 9 September 2026. With Bupa patient consultations winding down, Vitura says it is aligning Doctors on Demand’s infrastructure with anticipated volumes and pursuing strategic B2B and B2C pipelines. That creates a specific execution risk inside an otherwise positive quarter: revenue has beaten expectations, but the cost base must now adjust to the post-transition mix.
Emerging products add growth but remain forecast-dependent
Nicotine Vaping Product revenue more than doubled from the prior corresponding period, rising 107% in Q1 FY2027, with Vitura forecasting that the category will exceed its FY2027 expectations. Cortexa, the company’s 50%-owned joint venture, continues to supply products supporting Emyria’s expansion into Sydney, while the addition of Curaleaf broadened Vitura’s supplier network and product range.
Those emerging businesses diversify the revenue base, but the company’s forecasts remain forward-looking and the announcement provides no absolute revenue contribution for the segment. The next useful evidence will be whether the first-quarter cost and margin improvements hold through the Bupa transition, and whether Vitura can turn its new plan into reported profitability rather than simply a better starting quarter.
Bottom Line?
The first-quarter numbers give Vitura’s recovery plan credibility, but the decisive evidence will come from reported profit and cash performance after Bupa volumes unwind.
Questions in the middle?
- Can Vitura sustain the 9.5% reduction in operating expenditure as it pursues new B2B and B2C telehealth volumes?
- Will Doctors on Demand retain its revenue momentum once Bupa-related consultations have fully wound down?
- When will the Three Horizon Plan translate into reported profitability and clearer margin stability?